Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
AstraZeneca
McKesson
Baxter
Dow
Citi
Teva
Mallinckrodt
Argus Health

Generated: January 19, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021036

« Back to Dashboard

NDA 021036 describes RELENZA, which is a drug marketed by Glaxosmithkline and is included in one NDA. It is available from two suppliers. Additional details are available on the RELENZA profile page.

The generic ingredient in RELENZA is zanamivir. Two suppliers are listed for this compound. Additional details are available on the zanamivir profile page.
Summary for 021036
Tradename:RELENZA
Applicant:Glaxosmithkline
Ingredient:zanamivir
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 021036
Mechanism of ActionNeuraminidase Inhibitors
Medical Subject Heading (MeSH) Categories for 021036
Suppliers and Packaging for NDA: 021036
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
RELENZA zanamivir POWDER;INHALATION 021036 NDA GlaxoSmithKline LLC 0173-0681 0173-0681-01 5 PACKAGE in 1 CARTON (0173-0681-01) > 4 POWDER in 1 PACKAGE
RELENZA zanamivir POWDER;INHALATION 021036 NDA Dispensing Solutions Inc. 68258-3030 68258-3030-1 5 PACKAGE in 1 CARTON (68258-3030-1) > 4 POWDER in 1 PACKAGE

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:POWDER;INHALATIONStrength5MG
Approval Date:Jul 26, 1999TE:RLD:Yes

Expired US Patents for NDA 021036

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline RELENZA zanamivir POWDER;INHALATION 021036-001 Jul 26, 1999 ➤ Try a Free Trial ➤ Try a Free Trial
Glaxosmithkline RELENZA zanamivir POWDER;INHALATION 021036-001 Jul 26, 1999 ➤ Try a Free Trial ➤ Try a Free Trial
Glaxosmithkline RELENZA zanamivir POWDER;INHALATION 021036-001 Jul 26, 1999 ➤ Try a Free Trial ➤ Try a Free Trial
Glaxosmithkline RELENZA zanamivir POWDER;INHALATION 021036-001 Jul 26, 1999 ➤ Try a Free Trial ➤ Try a Free Trial
Glaxosmithkline RELENZA zanamivir POWDER;INHALATION 021036-001 Jul 26, 1999 ➤ Try a Free Trial ➤ Try a Free Trial
Glaxosmithkline RELENZA zanamivir POWDER;INHALATION 021036-001 Jul 26, 1999 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
AstraZeneca
Cipla
Fuji
McKinsey
Argus Health
Boehringer Ingelheim
Federal Trade Commission
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.